Skip to content
God Of Sound – Lifestyle
Author:
RenovoRx, Inc.
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
October 22, 2026
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
October 7, 2026
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform’s Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
October 1, 2026
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
September 2, 2026
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
August 29, 2026
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
August 20, 2026
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
August 12, 2026
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
August 11, 2026
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
August 6, 2026
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th
August 4, 2026
1
2
Next Page
→